This is potentially massive news for IHL. Seeing these results out of CBD alone is incredibly encouraging when all of the pre-clinical work announced by IHL to date regarding IHL 675A has demonstrated significant outperformance in relation to CBD alone.
Apart from this advancement in relation to treatment of Covid there is real potential now that 675A could become the gold standard in the treatment of inflammatory conditions for which CBD is extensively used on its own globally.
This could be an exciting ride,
Ted.
IHL Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held